Abstract
Palliative care has been shown to improve quality of life and even prolong life in patients with certain types of malignancy and end-organ failure. Several studies have now demonstrated a beneficial impact of palliative care on the transplant patient. While hospice provides care for patients whose survival is expected to be less than 6 months, palliative care is the specialized care for the patient with serious illness and can be provided at any stage of the disease. All transplant candidates, by definition, qualify. Like transplant medicine, palliative care is also interdisciplinary. It is person/family centered and provides support along with aggressive symptom management. Patients are screened for pain and other physical symptoms as well as for psychosocial and spiritual distress. Palliative care also fosters communication between the patient/family and health-care providers. The patient’s values and principles are elicited so that concordant medical care is provided. Implementing palliative care, sometimes referred to as supportive care early in the disease trajectory has helped transition patients into hospice care once curative options have been exhausted. This chapter will elucidate why patients with organ failure who are candidates for transplantation or patients suffering from complications of transplantation are excellent candidates for palliative care and why a palliative care provider should be part of the transplant interdisciplinary team.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Health Resources and Services Administration, Organ Procurement and Transplantation Network. Available at: https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/
Bloom RD, Goldberg LR, Wang AY, et al. An overview of solid organ transplantation. Clin Chest Med. 2005;26:529–43.
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small cell lung cancer. N Engl Med. 2010;363(8):733–42.
Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the project ENABLE II randomized controlled trial. JAMA. 2009;302:741–9.
World Health Organization. Available at: http://www.who.int/cancer/palliative/definition/en/
Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma – with particular reference to bronchogenic carcinoma. Cancer. 1948;1(4):634–56.
Palliative Performance Scale (PPSv2) version 2. Medical Care of the Dying, 4th ed., p. 121. ©Victoria Hospice Society, 2006.
Jaarsma T, Beattie JM, Ryder M, Rutten FH, McDonagh T, Mohacsi P, Advanced Heart Failure Study Group of the HFA of the ESC, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the heart failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:433–43. European Society of Cardiology.
Adler ED, Goldfinger JZ, Kalman J, et al. Contemporary reviews in cardiovascular medicine. Palliative care in the treatment of advanced heart failure. Circulation. 2009;120:2597–606.
Hardin KA, Meyers M, Louie S. Integrating palliative Care in Severe Chronic Obstructive Lung Disease. COPD. 2008;5(4):207–20.
Hope AA, Morrison RS. Integrating palliative care with chronic liver disease care. J Palliat Care. 2011;27(1):20–7.
Holley JL. Palliative care in end-stage renal disease: illness trajectories, communication, and hospice use. Adv Chronic Kidney Dis. 2007;14(4):402–8.
Singer PA, Martin DK, Kelner M. Quality end-of-life care: patents’ perspectives. JAMA. 1999;281:163–8.
Teno JM, Clarridge BR, Casey V, et al. Family perspectives on end-of-life care at the last place of care. JAMA. 2004;291(1):88–93.
Medicare part A: medicare hospice benefits. Available at: http://www.medicare.gov/Pubs/pdf/02154.pdf
Higginson IJ, Sen-Gupta GJ. Place of care in advanced cancer qualitative systematic literature review of patient preferences. J Palliat Med. 2000;3(3):287–300.
Murphy SL, Xu J, et al. Deaths: final data for 2015. National vital statistics report Vol 66. No 6 November 27, 2017.
Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2018;137(25)
American Heart Association. Classes of heart failure. Available at: http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp
Blinderman CD, Homel P, Billings JA, Portenoy RK, Tennstedt SL. Symptom distress and quality of life in patients with advanced heart failure. J Pain Symptom Manag. 2008;35(6):594–603.
Levenson JW, McCarthy EP, Lynn J, et al. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc. 2000;48(5 Suppl):S101–9.
Nordgren L, Sörensen S. Symptoms experienced in the last six months of life in patients with end-stage heart failure. Eur J Cardiovasc Nurs. 2003;2:213–7.
Levy WC, Mozaffarian D, Linker DT, et al. The seattle heart failure model: prediction of survival in heart failure. Circulation. 2006;113(11):1424–33.
Goda A, Williams P, Manicini D, et al. Selecting patients for heart transplantation: comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM). J Heart Lung Transplant. 2011;30(11):1236–43.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61.
Schwarz ER, Baraghoush A, Morrissey RP, et al. Pilot study of palliative care consultation in patients with advanced heart failure referred for cardiac transplantation. J Palliat Med. 2012;15(1):12–5.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2018 report. www.goldcopd.org. Accessed 25 Sept 2018.
GOLD. 2017 Global strategy for the diagnosis, management and prevention of COPD. http://goldcopd.org
Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38.
Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:653–61.
Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez PR. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–31.
Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med. 1996;154:959–67.
Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–52.
Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax. 2000;55(12):1000–6.
Connor SR, Pyenson B, Flitch K, et al. Comparing hospice and nonhospice patient survival among patients who die within a three year window. J Pain Symptom Manage. 2007;33(3):238–46.
Brumley R, Enguidanos S, Cherin D. Effectiveness of a homebase palliative care program for end-of-life. J Palliat Med. 2003;6:715–72438.
Lanken PN, Terry PB, Delisser HM, Fahy BF, Hansen-Flaschen J, Heffner JE, et al. ATS end-of-life care task force. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illness. Am J Respir Crit Care Med. 2008;177(8):912–27.
Zipprich A, Garcia-Tsao G, Rogowski S. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012;32(9):1407–14.
Llach J, Ginès P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988;94:482–7.
Arroyo V, Gine SP, Alexander L. Definition and diagnostic criteria ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23(1):164–76.
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.
Lamba S, Murphy P, McVicker S. Changing end-of-life care practice for liver transplant service patients: structured palliative care intervention in the surgical intensive care unit. J Pain Symptom Manag. 2012;44(4):508–19.
Singh N, Gayowski T, Wagener MM. Depression in patients with cirrhosis: impact on outcome. Dig Dis Sci. 1997;42(7):1421–7.
Marchesini G, Bianchi G, Amodio P, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology. 2001;120(1):170–8.
Roth K, Lynn J, Zhong Z, et al. Dying with end stage liver disease with cirrhosis: insights from SUPPORT. Study to understand prognoses and preferences for outcomes and risks of treatment. J Am Geriatr Soc. 2000;48(5 Suppl):S122–30.
KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal Dialysis adequacy and vascular access. Am J Kidney Dis. 2006;48(suppl 1):S1–322.
Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005;454(4):658–66.
The 2008 United States Renal Data System (USRDS) annual data report. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT. Physical symptoms and quality of life in patients on chronic dialysis: results of The Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD). Nephrol Dial Transplant. 1999;14:1163–70.
Lee BO, Lin CC, Chaboyer W, Chiang CL, Hung CC. The fatigue experience of hemodialysis patients in Tai- wan. J Clin Nurs. 2007;16:407–13.
McCann K, Boore JR. Fatigue in persons with renal failure who require maintenance haemodialysis. J Adv Nurs. 2000;32:1132–42.
Kimmel PL, Emont SL, Newmann JM, Danko H, Moss AH. ESRD patient quality of life: symptoms, spiritual beliefs, psychosocial factors, and ethnicity. Am J Kidney Dis. 2003;42:713–21.
Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Cruz I, Veis JH. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int. 2000;57:2093–8.
Moreno F, Lopez Gomez JM, Sanz-Guajardo D, et al. Quality of life in dialysis patients. A Spanish multicentre study. Spanish Cooperative Renal Patients Quality of Life Study Group. Nephrol Dial Transplant. 1996;11(Suppl 2):125–9.
Mingardi G, Cornalba L, Cortinovis E, et al. Health-related quality of life in dialysis patients. A report from an Italian study using the SF-36 Health Survey. DIA-QOL Group. Nephrol Dial Transplant. 1999;14(6):1503–10.
Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in end stage renal disease patients. Am J Kidney Dis. 2001;38(3):443–64.
Kasiske BL, Snyder JJ, Matas MD, Ellison MD, Gill JS, Kausz AT. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol. 2002;13:1358–64.
Abecassis M, Bartlett ST, et al. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) conference. Clin J Am Soc Nephrol. 2008;3(2):471–80.
D’Souza A, Zhu X. Current uses and outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR summary slides; 2016. Available at: http://www.cibmtr.org
American Society for Blood and Marrow Transplantation. Transplant referral guidelines. Available at: http://www.asbmt.org
Saleh US, Brockopp DY. Quality of life one year following bone marrow transplantation: psychometric evaluation of the quality of life in bone marrow transplant survivors tool. Oncol Nurs Forum. 2001;28(9):1457–64.
Andrykowski MA. Psychiatric and psychological aspects of bone marrow transplantation. Psychosomatics. 1994;35:13–24.
Lesko LM. Psychiatric aspects of bone marrow transplantation: part I. Special issues during pre-transplant assessment and hospitalization. Psychooncology. 1993;2:161–83.
Fife BL, Huster GA, Cornetta KG, Kennedy VN, Akard LP, Broun ER. Longitudinal study of adaptation to the stress of bone marrow transplantation. J Clin Oncol. 2000;18(7):1539–49.
Baker F, Marcellus D, Zabora J, et al. Psychological distress among adult patients being evaluated for bone marrow transplantation. Psychosomatics. 1997;38:10–9.
El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF, et al. Effect of inpatient palliative care on quality of life 2weeks after hematopoietic stem cell transplantation. JAMA. 2016;316(20):2094–103.
Lamon EB, Christakis NA. Some elements of prognosis in terminal cancer. Oncology (Willston Park). 1999;13(8):1165–70.
Heyland DK, Allan DE, Rocker G, et al. Discussing prognosis with patients and their families near the end of life: impact on satisfaction with end-of-life care. Open Med. 2009;3(2):e101–10.
Repetto L, Piselli P, Raffaele M, et al. Communicating cancer diagnosis and prognosis: when the target is the elderly patient-a GIOGER study. Eur J Cancer. 2009;45(3):374–83.
SUPPORT Principal Investigators. A controlled trial to improve care for seriously ill hospitalized patients. JAMA. 1995;274:1591–8.
Homsi J, Walsh D, Nelson KA, et al. The impact of palliative medicine consultation service in medical oncology. Support Care Cancer. 2002;10(4):337–42.
Rich A. How long have I got? Prognostication and palliative care. Eur J Palliat Care. 1999;6:179–82.
Christakis N. Death Foretold: prophecy and prognosis in medical care. Chicago: Chicago University Press; 1999.
Virik K, Glare P. Validation of the palliative performance scale for inpatients admitted to a palliative care unit in Sydney, Australia. J Pain Symptom Manag. 2002;23(6):455–7.
Olajide O, Hanson L, Usher BM, Qaqish BF, Schwartz R, Bernard S. Validation of the palliative performance scale in the acute tertiary care hospital setting. J Palliat Med. 2007;10(1):111–7.
Harrold J, Rickerson E, Carroll JT, McGrath J, et al. Is the palliative performance scale a useful predictor of mortality in a heterogeneous hospice population? J Palliat Med. 2005;8(3):503–9.
Head B, Ritchie CS, Smoot TM. Prognostication in hospice care: can the palliative performance scale help? J Palliat Med. 2005;8(3):492–502.
Morita T, Tsunod J, Inoue S, et al. Validity of the palliative performance scale from a survival perspective. J Pain Symptom Manag. 1999;18(1):2–3.
Poses RM, Smith WR, McClish DK, et al. Physicians’ survival predictions for patients with acute congestive heart failure. Arch Intern Med. 1997;157(9):1001–7.
National Hospice and Palliative Care Organization (NHPCO). https://www.nhpco.org/
National Hospice and Palliative Care Organization. Medical guidelines for determining prognosis in selected non-cancer diseases, 2nd ed. Arlington: National Hospice Organization; 1997, J Pain Palliat Care Pharmacother. 1996;11(2).
Brumley RD, Enguidanos S, Cherin DA. Effectiveness of a home-based palliative care program for end-of-life. J Palliat Med. 2003;6:715–24.
O’Brien T, Welsh J, Dunn FG. ABC of palliative care. Non malignant conditions. BMJ. 1998;316(7127):286–9.
Janssen DJ, Spruit MA, Wouters EF, Schols JM. Daily symptom burden in end-stage chronic organ failure: a systematic review. Palliat Med. 2008;22:938–48.
Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag. 2006;31:58–69.
Schickedanz A, Schillinger D, Landefeld CS. A clinical framework for improving the advance care planning process: start with patient’ self-identified barriers. J Am Geriatr Soc. 2009;57(1):31–9; quiz 62.
Wright L, Pape D, Ross K, Campbell M, Bowman K. Approaching end-of-life care in organ transplantation: the impact of transplant patients’ death and dying. Prog Transplant. 2007;17(1):57–61.
Gourdji I, McVey L, Purden M. A quality end of life from a palliative care patient’s perspective. J Palliat Care. 2009;25(1):40–50.
Hanson LC, Danis M, Garrett J. What is wrong with end-of-life care? Opinions of bereaved family members. J Am Geriatr Soc. 1997;45(11):1339–44.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendix
Appendix
Karnofsky Performance Status
100 | Normal, no complaints, no evidence of disease |
90 | Able to carry on normal activity, some minor symptoms of disease |
80 | Normal activity with effort: some symptoms of disease |
70 | Able to care for self but unable to carry on normal activity or active work |
60 | Requires occasional assistance but is able to care for most of personal needs |
50 | Requires considerable assistance and frequent medical care |
40 | Disabled: requires special care and assistance |
30 | Severely disabled: hospitalization is indicated, death not imminent |
20 | Very sick, hospitalization necessary: active treatment necessary |
10 | Moribund, fatal processes progressing rapidly |
0 | Death |
Palliative Performance Scale (PPSv2) [87] Reprinted with permission from Victoria Hospice Society , BC, Canada (2001) www.victoriahospice.org
Ambulation | Activity and evidence of disease | Self-Care | Intake | Conscious level | |
---|---|---|---|---|---|
100% | Full | Normal activity and work. No evidence of disease | Full | Normal | Full |
90% | Full | Normal activity and work. Some evidence of disease | Full | Normal | Full |
80% | Full | Normal activity with effort. Some evidence of disease | Full | Normal or reduced | Full |
70% | Reduced | Unable normal job/work. Significant disease | Full | Normal or reduced | Full |
60% | Reduced | Unable hobby/house work. Significant disease | Occasional assistance necessary | Normal or reduced | Full or confusion |
50% | Mainly sit/lie | Unable to do any work. Extensive disease | Considerable assistance required | Normal or reduced | Full or confusion |
40% | Mainly in bed | Unable to do most activity. Extensive disease | Mainly assistance | Normal or reduced | Full or drowsy +/− confusion |
30% | Totally bed bound | Unable to do any activity. Extensive disease | Total care | Normal or reduced | Full or drowsy +/− confusion |
20% | Totally bed bound | Unable to do any activity. Extensive disease | Total care | Minimal to sips | Full or drowsy +/− confusion |
10% | Totally bed bound | Unable to do any activity. Extensive disease | Total care | Mouth care only | Drowsy or coma +/− confusion |
0% | Death | – | – | – | – |
Instructions for Use of PPS (See also Definition of Terms)
-
1.
PPS scores are determined by reading horizontally at each level to find a “best fit” for the patient which is then assigned as the PPS% score.
-
2.
Begin at the left column and read downwards until the appropriate ambulation level is reached, then read across to the next column and downwards again until the activity/evidence of disease is located. These steps are repeated until all five columns are covered before assigning the actual PPS for that patient. In this way, “leftward” columns (columns to the left of any specific column) are “stronger” determinants and generally take precedence over others.
-
Example 1: A patient who spends the majority of the day sitting or lying down due to fatigue from advanced disease and requires considerable assistance to walk even for short distances but who is otherwise fully conscious level with good intake would be scored at PPS 50%.
-
Example 2: A patient who has become paralyzed and quadriplegic requiring total care would be PPS 30%. Although this patient may be placed in a wheelchair (and perhaps seem initially to be at 50%), the score is 30% because he or she would be otherwise totally bed bound due to the disease or complication if it were not for caregivers providing total care including lift/transfer. The patient may have normal intake and full conscious level. Example 3: However, if the patient in example 2 was paraplegic and bed bound but still able to do some self-care such as feed themselves, then the PPS would be higher at 40 or 50% since he or she is not “total care”.
-
-
3.
PPS scores are in 10% increments only. Sometimes, there are several columns easily placed at one level but one or two which seem better at a higher or lower level. One then needs to make a “best fit” decision. Choosing a “half-fit” value of PPS 45%, for example, is not correct. The combination of clinical judgment and “leftward precedence” is used to determine whether 40 or 50% is the more accurate score for that patient.
-
4.
PPS may be used for several purposes. First, it is an excellent communication tool for quickly describing a patient’s current functional level. Second, it may have value in criteria for workload assessment or other measurements and comparisons. Finally, it appears to have prognostic value.
Copyright © 2001 Victoria Hospice Society
Definition of Terms for PPS
As noted below, some of the terms have similar meanings with the differences being more readily apparent as one reads horizontally across each row to find an overall “best fit” using all five columns.
-
1.
Ambulation
The items mainly sit/lie, mainly in bed, and totally bed bound are clearly similar. The subtle differences are related to items in the self-care column. For example, “totally bed ‘bound’ at PPS 30% is due to either profound weakness or paralysis such that the patient not only can’t get out of bed but is also unable to do any self-care. The difference between ‘sit/lie’ and ‘bed’ is proportionate to the amount of time the patient is able to sit up vs need to lie down.”
Reduced ambulation is located at the PPS 70% and PPS 60% level. By using the adjacent column, the reduction of ambulation is tied to inability to carry out their normal job, work occupation or some hobbies or housework activities. The person is still able to walk and transfer on their own but at PPS 60% needs occasional assistance.
-
2.
Activity and Extent of disease
Some, significant, and extensive disease refer to physical and investigative evidence which shows degrees of progression. For example in breast cancer, a local recurrence would imply “some” disease; one or two metastases in the lung or bone would imply “significant” disease, whereas multiple metastases in the lung, bone, liver, brain, hypercalcemia, or other major complications would be “extensive” disease. The extent may also refer to progression of disease despite active treatments. Using PPS in AIDS, “some” may mean the shift from HIV to AIDS, and “significant” implies progression in physical decline, new or difficult symptoms, and laboratory findings with low counts. “Extensive” refers to one or more serious complications with or without continuation of active antiretrovirals, antibiotics, etc.
The above extent of disease is also judged in context with the ability to maintain one’s work and hobbies or activities. Decline in activity may mean the person still plays golf but reduces from playing 18 holes to 9 holes, or just a par 3, or to backyard putting. People who enjoy walking will gradually reduce the distance covered, although they may continue trying, sometimes even close to death (e.g., trying to walk the halls).
-
3.
Self-Care
Occasional assistance means that most of the time patients are able to transfer out of bed, walk, wash, go to toilet, and eat by their own means but that on occasion (perhaps once daily or a few times weekly) they require minor assistance.
Considerable assistance means that regularly every day, the patient needs help, usually by one person, to do some of the activities noted above. For example, the person needs help to get to the bathroom but is then able to brush his or her teeth or wash at least hands and face. Food will often need to be cut into edible sizes but the patient is then able to eat of his or her own accord.
Mainly assistance is a further extension of “considerable.” Using the above example, the patient now needs help getting up but also needs assistance washing his face and shaving, but can usually eat with minimal or no help. This may fluctuate according to fatigue during the day.
Total care means that the patient is completely unable to eat without help, go to toilet, or do any self-care. Depending on the clinical situation, the patient may or may not be able to chew and swallow food once prepared and fed to him or her.
-
4.
Intake
Changes in intake are quite obvious with normal intake referring to the person’s usual eating habits while healthy. Reduced means any reduction from that and is highly variable according to the unique individual circumstances. Minimal refers to very small amounts, usually pureed or liquid, which are well below nutritional sustenance.
-
5.
Conscious Level
Full consciousness implies full alertness and orientation with good cognitive abilities in various domains of thinking, memory, etc. Confusion is used to denote presence of either delirium or dementia and is a reduced level of consciousness. It may be mild, moderate or severe with multiple possible etiologies. Drowsiness implies either fatigue, drug side effects, delirium, or closeness to death and is sometimes included in the term stupor. Coma in this context is the absence of response to verbal or physical stimuli; some reflexes may or may not remain. The depth of coma may fluctuate throughout a 24-h period.
© Copyright Notice.
The Palliative Performance Scale version 2 (PPSv2) tool is copyright to Victoria Hospice Society and replaces the first PPS published in 1996 [J Pall Care 9(4): 26-32]. It cannot be altered or used in any way other than as intended and described here. Programs may use PPSv2 with appropriate recognition. Available in electronic Word format by email request to edu.hospice@viha.ca
Correspondence should be sent to Director Education and Research, Victoria Hospice Society, 1952 Bay Street, Victoria, BC, V8R 1J8, Canada
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this chapter
Cite this chapter
Ayala, J.S., Lowy, J. (2019). The Use of Palliative Care in Organ Transplant Patients and End-of-Life Issues. In: Safdar, A. (eds) Principles and Practice of Transplant Infectious Diseases. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-9034-4_60
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9034-4_60
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-9032-0
Online ISBN: 978-1-4939-9034-4
eBook Packages: MedicineMedicine (R0)